北京市中伦律师事务所 关于甘李药业股份有限公司 2022 年限制性股票激励计划第二个解除限售期解除 限售条件成就、2024 年限制性股票激励计划第一个 解除限售期解除限售条件成就、回购注销部分限制 性股票及调整回购价格的 法律意见书 二〇二五年五月 2022 年限制性股票激励计划第二个解除限售期解除限售条件成 就、2024 年限制性股票激励计划第一个解除限售期解除限售条 件成就、回购注销部分限制性股票及调整回购价格的 法律意见书 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-044 三、控股股东质押事项对公司的影响 截至本公告披露日，公司控股股东及实际控制人甘忠如先生所持公司股份已 全部解除质押，本次解除质押事项不会对公司生产经营产生实质性影响。 重要内容提示: 一、本次股份质押解除情况 | 股东名称 | 甘忠如 | | | | --- | --- | --- | --- | | 本次解除质押股份 | 14,210,000 | 股 | | | 占其所持股份比例 | 6.91% | | | | 占公司总股本比例 | 2.36% | | | | 解除质押/冻结/标记时间 | 2025 年 6 | 16 日 | 月 | | 直接持股数量 | 205,643,757 | 股 | | | 持股比例 | 34.21% | | | | 剩余被质押/冻结/标记股份数量 | 0 股 | | | 甘李药业股份有限公司（以下简称"公司"）控股股东及实际控制人甘忠如 先生持有公司股份 205,643,757 股，占公司总股本的 34.21%。2025 年 6 月 17 日公司收到通知，甘忠如先生已于近日办理完毕 14,210,000 股公司 ...

| 证券代码：603087 证券简称：甘李药业 公告编号：2025-044 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 甘李药业股份有限公司 | | | | | | | | | | | | | | 关于公司控股股东及实际控制人部分股份解押的公 | | | | | | | | | | | | | | 告 | | | | | | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | | | | | | | 重要内容提示: | | | | | | | | | | | | | | ? 甘李药业股份有限公司（以下简称"公司"）控股股东及实际控制人甘忠如 | | | | | | | | | | | | | | 205,643,757 34.21%。2025 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-043 甘李药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 甘李药业股份有限公司（以下简称"公司"）于 2025 年 5 月 20 日召开了 案》。5 月 30 日，公司召开第五届董事会第一次会议，审议通过了《关于公司 选举董事长的议案》，选举陈伟先生为公司第五届董事会董事长，任期至第五届 董事会届满。 根据《公司章程》的规定，陈伟先生担任公司法定代表人。公司已于近日完 成了法定代表人变更的工商登记手续，并取得了北京市通州区市场监督管理局换 发的《营业执照》。公司新营业执照法定代表人变更为陈伟先生，原营业执照其 他登记事项未发生变更。 变更后的《营业执照》基本信息如下： 名称：甘李药业股份有限公司 统一社会信用代码：91110000102382249M 法定代表人：陈伟 注册资本：人民币 60106.529 万元 成立日期：1998 年 6 月 17 日 住所：北京市通州区漷县镇南风西一路 8 号 经营范围：研制生物制品、生物原料药、小容量重组产 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-043 甘李药业股份有限公司 关于变更法定代表人并换发营业执照的公告 根据《公司章程》的规定，陈伟先生担任公司法定代表人。公司已于近日完 成了法定代表人变更的工商登记手续，并取得了北京市通州区市场监督管理局换 发的《营业执照》。公司新营业执照法定代表人变更为陈伟先生，原营业执照其 他登记事项未发生变更。 成立日期：1998 年 6 月 17 日 住所：北京市通州区漷县镇南风西一路 8 号 变更后的《营业执照》基本信息如下： 名称：甘李药业股份有限公司 统一社会信用代码：91110000102382249M 类型：股份有限公司（外商投资、上市） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 法定代表人：陈伟 甘李药业股份有限公司（以下简称"公司"）于 2025 年 5 月 20 日召开了 2024 年年度股东大会审议通过了《关于选举公司第五届董事会非独立董事的议 案》。5 月 30 日，公司召开第五届董事会第一次会议，审议通过了《关于公司 选举董事长的议案》，选举 ...

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Viewpoints - The report highlights the upcoming 85th Annual Scientific Sessions of the American Diabetes Association (ADA) from June 20-23, 2025, which is expected to showcase significant advancements in GLP-1 class drugs and weight management strategies [5][6] - The report emphasizes the increasing international recognition of China's innovations in the endocrine and metabolic fields, particularly in the GLP class drug sector, with notable achievements from companies like Innovent Biologics and Eli Lilly [7][8] - The report anticipates a substantial growth in China's GLP-1 weight loss drug market, projecting a market size exceeding 15 billion yuan by 2025, with penetration rates expected to rise from under 5% in 2023 to 18%-20% [8] Summary by Sections Recent Industry Performance - The industry has shown relative returns of 8.85% over the past month, 10.28% over the past three months, and 3.81% over the past year compared to the CSI 300 index [3] Investment Highlights - The report focuses on the catalysts from the ADA conference, particularly the advancements in GLP-1 class drugs, which are expected to drive investment opportunities [6][7] - Key companies mentioned include Eli Lilly, Novo Nordisk, and domestic firms like Boryung Pharmaceutical and Gan & Lee Pharmaceuticals, which are actively involved in GLP-1 drug development [7][8] Market Dynamics - The report notes the active business development transactions in the GLP class drug sector, indicating a high level of industry enthusiasm and potential for growth [7] - It also mentions the upcoming global diabetes-related conferences in 2025, which will further stimulate the market for GLP class drugs [8]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Investment Rating - Investment Rating: Buy (Maintain) [3] Core Views - The company reported a revenue of 3.045 billion yuan in 2024, representing a year-on-year growth of 16.77%, and a net profit attributable to shareholders of 615 million yuan, up 80.75% year-on-year, primarily due to significant gains from fair value changes of financial assets and disposal of financial assets [6][12] - In Q1 2025, the company achieved a revenue of 985 million yuan, a year-on-year increase of 75.76%, with a net profit of 312 million yuan, up 224.90% year-on-year [7][12] - The domestic insulin market is experiencing both volume and price increases, with domestic revenue in Q1 2025 reaching 889 million yuan, a growth of 80.07% year-on-year [8] - The company is expanding its overseas business, with overseas revenue in 2024 reaching 528 million yuan, a year-on-year increase of 23.89% [9] Financial Performance Summary - Revenue for 2025 is projected to be 4.393 billion yuan, with a year-on-year growth of 44.2%, and net profit is expected to reach 1.113 billion yuan, growing by 81.0% [12][14] - The company’s gross margin is expected to improve to 77.7% in 2025, with a return on equity (ROE) projected at 9.5% [14] - Earnings per share (EPS) for 2025 is estimated at 1.85 yuan, with a price-to-earnings (P/E) ratio of 30 times [12][14]

Core Viewpoint - The weight loss drug concept sector has seen a significant increase, with a rise of 4.66% as of June 9, positioning it as the second-highest gaining sector in the market [1]. Group 1: Market Performance - Within the weight loss drug sector, 48 stocks experienced gains, with Changshan Pharmaceutical reaching a 20% limit up [1]. - Notable gainers include Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical, all hitting the limit up, while Xinnoway and *ST Sansheng were among the few decliners [1]. - The sector's performance is reflected in the daily gainers and losers table, highlighting the overall positive trend in the weight loss drug concept [1]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 237 million yuan from major funds, with 27 stocks receiving net inflows [1]. - Zhongsheng Pharmaceutical led the net inflow with 247 million yuan, followed by Zhifei Biological, Shuanglu Pharmaceutical, and Ganli Pharmaceutical, which also saw significant inflows [1][2]. - The net inflow ratios for leading stocks in the sector were notably high, with Zhongsheng Pharmaceutical at 55.08%, indicating strong investor interest [2][3]. Group 3: Stock Performance Metrics - Key stocks in the weight loss drug sector showed impressive daily performance metrics, with Zhongsheng Pharmaceutical and Shuanglu Pharmaceutical both achieving nearly 10% gains [2][3]. - The turnover rates for these stocks also reflect active trading, with Zhongsheng Pharmaceutical at 3.84% and Shuanglu Pharmaceutical at 7.00% [2][3]. - The data indicates a robust interest in the weight loss drug sector, as evidenced by the high net inflow ratios and significant daily price movements [2][3].

Core Points - The company announced a cash dividend distribution of 1 yuan per share for its A shares, totaling approximately 597.53 million yuan (including tax) based on a total share capital of 601,065,290 shares, excluding 3,540,021 shares held in the repurchase account [1][2] - The dividend distribution plan was approved at the annual general meeting on May 20, 2025, and the key dates for the distribution are as follows: record date on June 10, 2025, last trading day on June 11, 2025, and ex-dividend date also on June 11, 2025 [1][2] - The company will not issue new shares or increase capital reserves, resulting in no change in the number of circulating shares, with a change ratio of "0" [2] Dividend Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1][2] - The actual cash dividend per share after tax for individual shareholders holding shares for more than one year will be 1 yuan, while for those holding shares for less than one month, the full amount will be subject to tax [4][6] - For qualified foreign institutional investors (QFII), the net cash dividend after a 10% withholding tax will be 0.90 yuan per share [5] Price Adjustment - Following the completion of the dividend distribution, the company will adjust the relevant prices associated with its equity incentive plans, with further details to be announced later [6]